Status:
WITHDRAWN
Evaluation of Low-dose Irinotecan and Cyberknife® SBRT to Treat Colorectal Cancer With Limited Liver Metastasis
Lead Sponsor:
Wake Forest University Health Sciences
Conditions:
Colorectal Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to determine the effects of CyberKnife stereotactic body radiotherapy in combination with irinotecan chemotherapy in patients with colon or rectal cancer that has spread t...
Eligibility Criteria
Inclusion
- Age\>18 years
- Histologically confirmed primary colorectal cancer
- Stage IV colorectal cancer with \</= 3 metastases, up to 5cm in size.
- CT scan or MRI of the abdomen with contrast, 60days prior to enrollment
- If patient is allergic to contrast, imaging without contrast is acceptable
- Positron-Emission Tomography 60 days prior to enrollment
- No additional sites of metastasis at the time of protocol enrollment. History of other sites of metastasis that are currently controlled are acceptable.
- No malignant ascites
- At least 4 weeks from any chemotherapy
- No prior liver radiation therapy
- ECOG performance status 0-1
- Life expectancy\>3months
- Laboratory evaluations completed 60 days prior to treatment including CMP, CBC with differential, liver function test, and prothrombin time.
Exclusion
Key Trial Info
Start Date :
October 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 29 2017
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01847495
Start Date
October 1 2013
End Date
November 29 2017
Last Update
October 4 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Advocate Lutheran General Hospital
Park Ridge, Illinois, United States, 60068